AlphAIAlphAI — Financial news for AI agents
theglobeandmail.com$LTGO

The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’

Goldman Sachs recommends two under-the-radar IPO stocks: Latigo Biotherapeutics (LTGO) and Braveheart Bio (BRVE). LTGO, which develops non-opioid pain relief drugs, raised $345.6M in its IPO and has a market cap of $1.5B. Goldman's analyst sets a $73 price target, implying a 217% gain. BRVE focuses on hypertrophic cardiomyopathy treatments and plans Phase 3 trials next year. Both stocks have unanimous 'Buy' ratings from analysts.

Original reporting
theglobeandmail.com
Published Sep 9, 2026, 10:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’ — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$LTGOBullishLow
01

Why it matters

Both companies are presented as undervalued opportunities, but the piece offers no new corporate disclosures, making the trading insight limited.

02

Market read

The piece is a recommendation roundup with low immediate trading relevance.

03

What to watch

Liquidity constraints of recent IPOs and possible dilution from future financing rounds.

Relevance 4/10Novelty 2/10Timing: post‑IPO recommendation

Background

The article reviews two recent biotech IPOs, Latigo Biotherapeutics (LTGO) and Braveheart Bio (BRVE), and cites Goldman Sachs analyst recommendations.

Company-level read

Ticker impact

$LTGOBullishMedium confidence
Context

Latigo Biotherapeutics (LTGO) IPO and Goldman Sachs buy rating with a $73 price target are highlighted as under‑the‑radar opportunities.

Expected impact

Potential short‑term upside if investors follow the buy rating.

Evidence & confidence

Buy rating is based on Phase 2b data and upcoming Phase 3 trials, but no new data released in this article.

$BRVEBullishMedium confidence
Context

Braveheart Bio (BRVE) IPO and positive Phase 2 trial results for its cardiomyopathy drug are presented as a hidden opportunity.

Expected impact

Modest upside if market reacts to the highlighted trial success.

Evidence & confidence

The article repeats existing trial results without new disclosures.

Market effects

Sector

Highlights potential growth in the non‑opioid pain‑relief and cardiomyopathy biotech sub‑sectors.

Regional

Focuses on U.S. IPO market activity in 2026.

Global

Limited to investors tracking new biotech listings.

Counterpoint

What could challenge this read

Without fresh clinical data, the buy ratings may be premature; investors should await Phase 3 results.

Key entities

  • company
    Latigo Biotherapeutics

    Clinical‑stage biotech focused on non‑opioid pain relief, IPO August 2026.

  • company
    Braveheart Bio

    Clinical‑stage biotech targeting hypertrophic cardiomyopathy, IPO August 2026.

  • analyst_firm
    Goldman Sachs

    Provides buy recommendations and price targets for the two IPOs.

Read at source← All news

Related articles

$BRVEMedAI 8/10

Braveheart Bio Reports Positive 52-Week HCM Study Data

Braveheart Bio (BRVE) and Hengrui Pharma presented 52-week Phase 2 study data for HRS/BHB-1893 in obstructive HCM, showing improved exercise capacity and patient outcomes. 79% of 42 patients achieved a Valsalva LVOT gradient below 30 mmHg. The treatment was well-tolerated, with 57% maintaining the starting dose. Analysts rate BRVE stock as Buy with a $40.00 target.

tipranks.com
$BRVEMedAI 8/10

Braveheart Bio Reports 52-Week HRS/BHB-1893 Data in Obstructive HCM

Braveheart Bio reported 52-week Phase 2 extension data for HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy, showing improvements in exercise capacity and patient outcomes. Key metrics: peak oxygen uptake increased by 2.7 mL/kg/min, KCCQ-CSS rose by 17.3 points, and 79% of patients had a Valsalva LVOT gradient below 30 mmHg. The company plans to discuss a Phase 2b study at an investor event.

tradingview.com
$BRVEHighAI 9/10

Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study

Braveheart Bio, Inc. (BRVE) filed an SEC Form 8-K — Regulation FD Disclosure. Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026 HRS/BHB-1893 demonstrated meaningful improvements in exercise capaci

SEC EDGAR 8-K
$BRVEMedAI 9/10

Braveheart Bio (BRVE) Reports 52-Week HCM Drug Study Results

Braveheart Bio (BRVE) reported 52-week study results for its HCM drug HRS/BHB-1893, showing improved exercise capacity and symptom scores in 42 patients. 79% had a Valsalva LVOT gradient below 30 mmHg, with no severe adverse events. The company is conducting further studies to establish efficacy and dosing.

tradingview.com